An epidemic of a novel coronavirus emerged from Wuhan, China, in late December 2019 and has since spread to other parts of China and several foreign countries. The 2019 novel coronavirus (2019-nCoV)pneumonia, which is believed to be an acute respiratory infectious disease, has been included among the Class B infectious diseases stipulated in the Law of the People’s Republic of China on the Prevention and Control of Infectious Diseases, and measures for prevention and control of Class A infectious diseases have been adopted for this disease. Thanks to the implementation of a series of countermeasures including prevention, control and medical treatments, the outbreak of the epidemic in China has been curbed to a certain extent and the situation in most of the provinces has been alleviated; nevertheless, the number of newly confirmed cases in foreign countries are on the rise. Based on the increased awareness of the clinical manifestations and pathological features of this disease and the accumulated experience in diagnosis and treatment, the Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia(The 6th Trial Edition) was revised and the 7th edition was developed, with the aims to provide clinical guidance for the diagnosis and treatment of the disease, improve the cure rate, reduce the mortality, minimize nosocomial infections, as well as raise awareness on the potential transmission and spreading of the virus caused by the imported cases.
